Significance of vascular stabilization for tumor growth and metastasis

Cancer Letters

Volumn 238, Issue 2, 2006, Pages 180-187

  Ergun, Suleyman ^a   Tilki, Derya ^a   Oliveira Ferrer, Leticia ^a   Schuch, Gunter ^a   Kilic, Nerbil ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anti angiogenic tumor; Microvasculature; Vascular stabilization

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ENDOSTATIN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CANCER THERAPY; HUMAN; MATURATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION; VASCULARIZATION;

EID: 33745009983     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.033     Document Type: Review

References (33)

1. Baluk P., Hashizume H., and McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 (2005) 102-111
2. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
3. McDonald D.M., and Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 62 (2002) 5381-5385
4. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 13 (2003) 159-167
5. Luttun A., and Carmeliet P. Angiogenesis and lymphangiogenesis: highlights of the past year. Curr. Opin. Hematol. 11 (2004) 262-271
6. Asahara T., and Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol Cell Physiol. 287 (2004) C572-C579
7. Gehling U.M., Ergun S., Schumacher U., Wagener C., Pantel K., Otte M., Schuch G., Schafhausen P., Mende T., Kilic N., Kluge K., Schafer B., Hossfeld D.K., and Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95 (2000) 3106-3112
8. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002) 826-835
9. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29 (2002) 10-14
10. Folkman J., and D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 87 (1996) 1153-1155
11. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 9 (2003) 713-725
12. Kalluri R. Angiogenesis: basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3 (2003) 422-433
13. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163 (2003) 1801-1815
14. Ergun S., Kilic N., Wurmbach J.H., Ebrahimnejad A., Fernando M., Sevinc S., Kilic E., Chalajour F., Fiedler W., Lauke H., Lamszus K., Hammerer P., Weil J., Herbst H., and Folkman J. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 4 (2001) 193-206
15. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
16. Kilic N., Lauke H., Fiedler W., Pottek T., Kilic E., Freeman M., and Ergun S. Angiogenic switch and vascular stability in human leydig cell tumours. Angiogenesis 3 (1999) 231-240
17. Vosseler S., Mirancea N., Bohlen P., Mueller M.M., and Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65 (2005) 1294-1305
18. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di T.E., Munn L.L., and Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
19. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
20. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
21. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
22. Hawighorst T., Skobe M., Streit M., Hong Y.K., Velasco P., Brown L.F., Riccardi L., Lange-Asschenfeldt B., and Detmar M. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol. 160 (2002) 1381-1392
23. Weber C.C., Cai H., Ehrbar M., Kubota H., Martiny-Baron G., Weber W., Djonov V., Weber E., Mallik A.S., Fussenegger M., Frei K., Hubbell J.A., and Zisch A.H. Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization. J. Biol. Chem. 280 (2005) 22445-22453
24. Hayes A.J., Huang W.Q., Mallah J., Yang D., Lippman M.E., and Li L.Y. Angiopoietin-1 and its receptor tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res. 58 (1999) 224-237
25. Papapetropoulos A., Garcia-Cardena G., Dengler T.J., Maisonpierre P.C., Yancopoulos G.D., and Sessa W.C. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. 79 (1999) 213-223
26. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., Glazer N., Holash J., McDonald D.M., and Yancopoulos G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6 (2000) 460-463
27. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., Fiedler W., and Ergun S. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia (2005)
28. Takahashi K., Saishin Y., Saishin Y., Silva R.L., Oshima Y., Oshima S., Melia M., Paszkiet B., Zerby D., Kadan M.J., Liau G., Kaleko M., Connelly S., Luo T., and Campochiaro P.A. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. (2003)
29. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., and Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation (2004)
30. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
31. Gratton J.P., Lin M.I., Yu J., Weiss E.D., Jiang Z.L., Fairchild T.A., Iwakiri Y., Groszmann R., Claffey K.P., Cheng Y.C., and Sessa W.C. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4 (2003) 31-39
32. Hansen-Algenstaedt N., Joscheck C., Schaefer C., Lamszus K., Wolfram L., Biermann T., Algenstaedt P., Brockmann M.A., Heintz C., Fiedler W., and Ruther W. Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. Eur. J. Cancer 41 (2005) 1073-1085
33. Bloch W., Huggel K., Sasaki T., Grose R., Bugnon P., Addicks K., Timpl R., and Werner S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 14 (2000) 2373-2376